Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MetRx "andro" ads

This article was originally published in The Tan Sheet

Executive Summary

MetRx revising ads for its fitness supplements to delete products containing androstenedione after ESPN and Fox Sports pulled the original ads in response to public outcry. The new ads are slated to air in late October. The controversy over the use of androstenedione is due to questions regarding its steroid nature and unknown side effects. MetRx is conducting several studies at Eastern Michigan University to determine the testosterone-related effects of androstenedione. In the first of five studies, the company is dosing eight male college-age subjects on a rotating basis with either placebo, 100 mg androstenedione or 100 mg androstenediol, a similar substance, with a three-day washout period between treatments, then comparing blood levels of testosterone to baseline at various points up to 90 minutes post-dose. MetRx says androstenediol is three times more potent than androstenedione. Testosterone levels for all subjects have remained within normal physiological levels

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088928

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel